Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine

View ORCID ProfileTimothée Bruel, Laurie Pinaud, Laura Tondeur, View ORCID ProfileDelphine Planas, Isabelle Staropoli, Françoise Porrot, Florence Guivel-Benhassine, Mikaël Attia, Stéphane Pelleau, Tom Woudenberg, Cécile Duru, Aymar Davy Koffi, Sandrine Castelain, Sandrine Fernandes-Pellerin, Nathalie Jolly, Louise Perrin De Facci, Emmanuel Roux, Marie-Noëlle Ungeheuer, Sylvie Van Der Werf, Michael White, View ORCID ProfileOlivier Schwartz, Arnaud Fontanet
doi: https://doi.org/10.1101/2022.03.30.22273175
Timothée Bruel
1Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
2Vaccine Research Institute, Créteil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Timothée Bruel
  • For correspondence: timothee.bruel@pasteur.fr arnaud.fontanet@pasteur.fr
Laurie Pinaud
3Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Tondeur
3Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Delphine Planas
1Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
2Vaccine Research Institute, Créteil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Delphine Planas
Isabelle Staropoli
1Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Françoise Porrot
1Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florence Guivel-Benhassine
1Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikaël Attia
4Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphane Pelleau
5Infectious Disease Epidemiology and Analytics Unit, Institut Pasteur, Université Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Woudenberg
5Infectious Disease Epidemiology and Analytics Unit, Institut Pasteur, Université Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cécile Duru
6Hôpital de Crépy-en-Valois, Crépy-en-Valois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aymar Davy Koffi
6Hôpital de Crépy-en-Valois, Crépy-en-Valois, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandrine Castelain
7Laboratoire de virologie, CHU Amiens, AGIR UR4294, UPJV, Amiens, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandrine Fernandes-Pellerin
8Center for Translational Science, Institut Pasteur, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Jolly
8Center for Translational Science, Institut Pasteur, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise Perrin De Facci
9Clinical Investigation and access to bioresources (ICAReB) platform, Center for Translational Science, Institut Pasteur, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel Roux
9Clinical Investigation and access to bioresources (ICAReB) platform, Center for Translational Science, Institut Pasteur, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Noëlle Ungeheuer
9Clinical Investigation and access to bioresources (ICAReB) platform, Center for Translational Science, Institut Pasteur, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie Van Der Werf
4Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael White
5Infectious Disease Epidemiology and Analytics Unit, Institut Pasteur, Université Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Schwartz
1Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
2Vaccine Research Institute, Créteil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olivier Schwartz
Arnaud Fontanet
3Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, Paris, France
10Conservatoire National des Arts et Métiers, PACRI Unit, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: timothee.bruel@pasteur.fr arnaud.fontanet@pasteur.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The protective immunity against Omicron following a BNT162b2 Pfizer booster dose among elderly is not well characterized.

Methods Thirty-eight residents from three nursing homes were recruited for the study. Antibodies targeting the Spike protein of SARS-CoV-2 were measured with the S-Flow assay. Neutralizing activities in sera were measured as effective dilution 50% (ED50) with the S-Fuse assay using authentic isolates of Delta and Omicron.

Results Among the 38 elderly included in the study, with median (inter-quartile range, IQR) age of 88 (81-92) years, 30 (78.9%) had been previously infected. The ED50 of neutralization were lower against Omicron than Delta, and higher among convalescent compared to naive residents. During an Omicron epidemic affecting two of the three nursing homes in December 2021-January 2022, 75% (6/8) of naive residents got infected, compared to 25% (6/24) of convalescents (P=0.03). Antibody levels to Spike and ED50 of neutralization against Omicron after the BNT162b2 booster dose were lower in those with breakthrough infection (n=12) compared to those without (n=20): median of 1256 vs 2523 BAU/mL (P=0.02) and median ED50 of 234 vs 1298 (P=0.0004), respectively.

Conclusion This study confirmed the importance of receiving at least three antigenic exposures to the SARS-CoV-2 Spike protein for achieving satisfactory neutralizing antibody levels. In this population, protection against Omicron infection was increased in individuals who had been previously infected in addition to the three vaccine doses. Thus, a fourth antigenic exposure may be useful in the elderly population to prevent infection with Omicron, a variant known for its high escape immunity properties.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Work in OS lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Medicale (FRM), the European Health Emergency Preparedness and Response Authority (HERA), ANRS-MIE, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito, and IDISCOVR, TIMTAMDEN ANR-14-CE14-0029, CHIKV-Viro- Immuno ANR-14-CE14-0015-01 and the Gilead HIV cure program. AF lab is funded by the INCEPTION project (PIA/ANR-16-CONV-0005) and the Labex IBEID (ANR-10-LABX-62-IBEID). The COVID-Oise cohort is funded by Alliance Tous Unis contre le virus Institut Pasteur, AP-HP and Fondation de France.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was registered with ClinicalTrials.gov (NCT04644159) and received ethical approval by the Comite de Protection des Personnes Nord Ouest IV. Informed consent was obtained from the residents, or their relatives when the residents did not have full capacity to sign legal documents.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Co-first authors

  • ↵** Co-last authors

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 30, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine
Timothée Bruel, Laurie Pinaud, Laura Tondeur, Delphine Planas, Isabelle Staropoli, Françoise Porrot, Florence Guivel-Benhassine, Mikaël Attia, Stéphane Pelleau, Tom Woudenberg, Cécile Duru, Aymar Davy Koffi, Sandrine Castelain, Sandrine Fernandes-Pellerin, Nathalie Jolly, Louise Perrin De Facci, Emmanuel Roux, Marie-Noëlle Ungeheuer, Sylvie Van Der Werf, Michael White, Olivier Schwartz, Arnaud Fontanet
medRxiv 2022.03.30.22273175; doi: https://doi.org/10.1101/2022.03.30.22273175
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine
Timothée Bruel, Laurie Pinaud, Laura Tondeur, Delphine Planas, Isabelle Staropoli, Françoise Porrot, Florence Guivel-Benhassine, Mikaël Attia, Stéphane Pelleau, Tom Woudenberg, Cécile Duru, Aymar Davy Koffi, Sandrine Castelain, Sandrine Fernandes-Pellerin, Nathalie Jolly, Louise Perrin De Facci, Emmanuel Roux, Marie-Noëlle Ungeheuer, Sylvie Van Der Werf, Michael White, Olivier Schwartz, Arnaud Fontanet
medRxiv 2022.03.30.22273175; doi: https://doi.org/10.1101/2022.03.30.22273175

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (949)
  • Dentistry and Oral Medicine (178)
  • Dermatology (111)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8997)
  • Forensic Medicine (4)
  • Gastroenterology (421)
  • Genetic and Genomic Medicine (1960)
  • Geriatric Medicine (191)
  • Health Economics (404)
  • Health Informatics (1330)
  • Health Policy (661)
  • Health Systems and Quality Improvement (520)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10822)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1835)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (356)
  • Occupational and Environmental Health (470)
  • Oncology (1000)
  • Ophthalmology (299)
  • Orthopedics (111)
  • Otolaryngology (183)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (582)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1908)
  • Public and Global Health (4128)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (550)
  • Rheumatology (226)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (82)